



Exton, PA November 18, 2020

# Pablo Alvarez appointed to President and GM of Almirall US

- Pablo will report directly to the CEO and serve on the Management Board effective immediately
- He brings to this important role broad international pharmaceutical industry experience, including nearly 10 years in the US
- Almirall US is poised for growth under strengthened leadership

<u>Almirall, S.A. (ALM)</u> a global medical dermatology company based in Barcelona, has announced that Pablo Alvarez has been promoted and will become the new President & GM of Almirall US, reporting directly to the CEO of the company. In addition, Pablo has been appointed to the Management Board in this new role, an important development which highlights the importance of the US organization to the company as a whole

Pablo has previously served as Commercial Operations Director, overseeing several market companies such as the UK, Netherlands, Nordics, Belgium and France, as well as heading a number of global functions, during which he gained extensive experience in medical dermatology.

Before joining Almirall, Pablo worked for Glaxo Smith Kline, Bristol Meyers Squibb and AstraZeneca including key positions in Europe, LatAm and China and, importantly, nine years in the US. He has deep experience in the pharmaceutical industry including launching products, implementing new business models, expanding to new geographies and strategy development. Pablo has a PhD in Pharmacy, with a focus on Microbiology from the Complutense University (Madrid, Spain), carried out a postdoctoral research at MIT (Boston, United States) and studied business and management at IESE Business School (Barcelona, Spain).

According to Peter Guenter, CEO of Almirall, "Pablo will immediately add value with his extensive international commercial experience. His appointment is a clear opportunity to further strengthen Almirall's presence in the US market, drive the uptake of Seysara® (sarecycline) and ensure a successful launch of tirbanibulin. Always with a clear focus on what is important for the business, he stands out for his great leadership, strategic thinking, analytical skills and ability to drive and manage change. We are proud of this internal promotion as it is an example of our commitment at Almirall towards our internal talent and the success of our talent review and succession planning process."

Pablo stated, "I am delighted to be leading a strong and experienced team, and to continue to build Almirall's presence and medical dermatology portfolio in the US. I am proud of the commitment to innovation and the patient centric approach that guides everything we do at Almirall, and I look forward to working with the team and the dermatology community in the US to bring further treatments that benefit those patients."

We would like to thank Ron Menezes for his work and dedication to the company during the last 3 years. We wish him all the best in his future projects in his home state of California.

## **About Almirall**

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

## For more information, please visit almirall.com

**EU Media contact:** Tinkle Pilar Colomer

pcolomer@tinkle.es Phone: (+34) 93 545 12 51

### **US Media contact:**

Almirall Samantha Widdicombe AlmirallPR.US@almirall.com Phone: (+1) 610 644 7000

#### Investor Relations contact Almirall

Pablo Divasson del Fraile pablo.divasson@almirall.com Phone: (+34) 93 291 3087

Phone: (+34) 93 291 30 00

**Corporate Communications contact:** Almirall Francesca Wuttke francesca.wuttke@almirall.com

#### Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication click here

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at https://www.almirall.com/privacy-policy or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy https://gdpr.cision.com/gdpr. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.